Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study

Mourad, Moustafa; Jetmore, Thomas; Jategaonkar, Ameya A.; Moubayed, Sami P.; Moshier, Erin; Urken, Mark L.

doi:10.1016/j.joms.2017.05.008

Cited by 227 publications

(227 citation statements)

References 26 publications

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…The proportion of male patients with vocal cord leukoplakia in the present study was 61.8%, which is at the lower end of the spectrum compared with the results of previous studies (6,25,26). In addition, the present study identified advanced age as a risk factor for the diagnosis of laryngeal carcinoma in patients with vocal cord leukoplakia.…”

Section: Discussioncontrasting

confidence: 48%

Association of laryngeal cancer with vocal cord leukoplakia and associated risk factors in 1,184 patients diagnosed in otorhinolaryngology practices in Germany

Kostev¹,

Jacob

Kalder

et al. 2018

mol clin onc

View full text Add to dashboard Cite

Abstract. The aim of the present study was to analyze the association between laryngeal cancer and vocal cord leukoplakia in a large nationwide practice database. The study sample included 1,184 patients aged 18-90 years from 113 otorhinolaryngology practices in Germany who were diagnosed with vocal cord leukoplakia between 2007 and 2014. The rates of laryngeal cancer diagnosis within 5 years and the associated risk factors were analyzed. Within 6 months of initial diagnosis of vocal cord leukoplakia, 11% of the patients were diagnosed with laryngeal cancer. Between 7 months and 5 years after the diagnosis of leukoplakia, laryngeal cancer was diagnosed in 7.6% of the patients. Overall, within 5 years of leukoplakia diagnosis, 18.6% of the patients were diagnosed with laryngeal cancer (26.1% of men and 6.3% of women; P<0.001). Moreover, 31.3% of patients aged >65 years, 16.1% of patients aged 50-65 years and 7.6% of patients aged <50 years were diagnosed with laryngeal cancer (P<0.001). Patients aged >65 and those aged 50-65 years had a higher risk of being diagnosed with laryngeal cancer [odds ratio (OR)=4.90 and 2.55, respectively]. Furthermore, the risk of being diagnosed with laryngeal cancer was higher in men compared with that in women (OR=4.09). In the present real-world analysis, the rate of laryngeal cancer underlying vocal cord leukoplakia at first diagnosis appeared to be higher compared with the secondary malignant transformation rate occurring later during the course of the disease. Risk factors for laryngeal cancer included advanced age and male sex.

show abstract

Section: Discussioncontrasting

confidence: 48%

Association of laryngeal cancer with vocal cord leukoplakia and associated risk factors in 1,184 patients diagnosed in otorhinolaryngology practices in Germany

Kostev¹,

Jacob

Kalder

et al. 2018

mol clin onc

View full text Add to dashboard Cite

show abstract

“…The incidence of HPV-related OPSCC among women remained generally plateaued (statistically insignificant increase of 0.57% per year) from 2002 to 2012 (3). In contrast, the incidence of OPSCC (7.8 per 100,000) among men has increased dramatically (2.89% per year) and has already surpassed the incidence of cervical cancer among women (7.4 per 100,000) (3).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…In contrast, the incidence of OPSCC (7.8 per 100,000) among men has increased dramatically (2.89% per year) and has already surpassed the incidence of cervical cancer among women (7.4 per 100,000) (3). The increase in annual incidence was particularly high among 50–59-year-old men—7.75% from 2002–2004 and 2.44% from 2004–2010 (3). It is projected that these trends in the incidence will continue and will not reverse until after 2060, making OPSCC a significant public health concern (4, 5).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014

et al. 2017

View full text Add to dashboard Cite

Background: The burden of human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma (OPSCC) is disproportionately high among men, yet empirical evidence regarding the differential prevalence of oral HPV infection by gender is limited. Concordance of oral and genital HPV infection among men is unknown. Objective: To determine the prevalence of oral HPV infection, and concordance of oral and genital HPV infection among US men and women. Design: Nationally representative survey. Setting: Civilian noninstitutionalized population. Participants: Participants aged 18–69 years from the National Health and Nutritional Examination Survey (2011–2014). Measurements: Oral rinse, penile swab, and vaginal swab specimens were evaluated using polymerase chain reaction followed by type-specific hybridization. Results: The overall prevalence of oral HPV among men and women was 11.5% (equating to 11 million men nationwide) and 3.2% (3.2 million), respectively. High-risk oral HPV (HR-HPV) prevalence was higher among men (7.3%) than in women (1.4%). Oral HPV-16 was 6-times more common in men (1.8%) than in women (0.3%), i.e., 1.7 million men compared with 0.27 million women. Among men and women who reported having same gender sex partners, prevalence of HR-HPV infection was 12.7% and 3.6%, respectively. Particularly, among men who reported having ≥2 same gender oral sex partners, prevalence was 22.2%. Oral HPV prevalence among men with concurrent genital HPV infection was 4-fold greater (19.3%) compared to men without genital HPV infection (4.4%). Gender and lifetime number of oral sex partners were associated with overall HPV, HR-HPV, concordant overall HPV, and concordant HR-HPV infection. Limitations: Sexual behaviors were self-reported. Conclusion: Oral HPV infection is common among US men. Our findings provide several policy implications to guide future OPSCC prevention efforts to combat this disease.

show abstract

“…Over the past two decades, the overall incidence of head and neck cancer in the United States has decreased, paralleling the nationwide reduction in tobacco abuse . In contrast, the rate of oropharyngeal carcinoma (OPSCC) has increased by 2% to 3% annually, a consequence of human papillomavirus (HPV) . HPV‐mediated (HPV+) and non–HPV‐mediated (HPV‐) disease is associated with different patient characteristics, biologic behavior, and oncologic outcomes, a distinction highlighted by newly constructed staging criteria for HPV+ and HPV− disease .…”

Section: Introductionmentioning

confidence: 99%

Practice patterns and outcomes following radiation dose de‐escalation for oropharyngeal cancer

et al. 2019

View full text Add to dashboard Cite

Objectives/Hypothesis Numerous trials are evaluating radiotherapy (RT) de‐escalation for human papillomavirus (HPV)‐mediated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). Herein, we evaluated the degree to which de‐escalated RT is delivered in the United States, as well as comparative outcomes with full‐dose RT as stratified for HPV status. Study Design Retrospective database review. Methods We identified patients diagnosed with OPSCC in the National Cancer Database, excluding those with stage I/II disease, unknown HPV status, receiving surgery or not receiving external beam radiation therapy to the primary site, receipt of radiation doses >75 or <54 Gy, radiation treatment course duration <25 or >75 days, and unknown or inadequate (<2 months) follow‐up. Multivariable logistic regression analysis identified variables associated with delivery of de‐escalated RT (<66 Gy). Overall survival of HPV+ and non–HPV‐mediated (HPV−) disease was compared between full‐dose and de‐escalated approaches. Results Altogether, 617 and 551 patients were HPV+ and HPV−, respectively. De‐escalated RT was delivered in 16.9% HPV+ and 15.2% of HPV− disease, respectively. Older patients and omission of systemic therapy were more likely to receive de‐escalated RT. In HPV+ patients, 3‐ and 5‐year survival rates were 83% and 80% in the de‐escalated cohort versus 83% and 78% in the full‐dose group (P = .83). In HPV− patients, corresponding 3‐ and 5‐year survival rates were 29% and 23% versus 61% and 51% (P = .001). Conclusions National utilization of de‐escalated RT for OPSCC is low (15%–20%), but does not seem to impact overall survival in HPV+ (but not HPV−) patients. The caveats of this heterogeneous, retrospective analysis require corroboration from a number of ongoing randomized trials. Level of Evidence 2c Laryngoscope, 130:E171–E176, 2020

show abstract

Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study

Cited by 227 publications

References 26 publications

Association of laryngeal cancer with vocal cord leukoplakia and associated risk factors in 1,184 patients diagnosed in otorhinolaryngology practices in Germany

Association of laryngeal cancer with vocal cord leukoplakia and associated risk factors in 1,184 patients diagnosed in otorhinolaryngology practices in Germany

Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014

Practice patterns and outcomes following radiation dose de‐escalation for oropharyngeal cancer

Contact Info

Product

Resources

About